🔗 Share this article

This year's Nobel Prize in Physiology or Medicine was granted for revolutionary discoveries that illuminate how the immune system targets harmful infections while sparing the body's own cells.

A trio of esteemed researchers—from Japan Shimon Sakaguchi and American scientists Mary Brunkow and Dr. Ramsdell—received this accolade.

The research identified unique "security guards" within the immune system that eliminate rogue defense cells that could harming the organism.

These discoveries are now enabling innovative therapies for immune disorders and cancer.

These winners will divide a prize fund worth 11m Swedish kronor.

Decisive Findings

"Their work has been decisive for understanding how the immune system functions and why we don't all develop severe self-attack conditions," commented the chair of the Nobel Committee.

This team's research explain a core question: In what way does the immune system defend us from countless infections while leaving our own tissues unharmed?

Our body's protection system employs white blood cells that search for signs of disease, including pathogens and germs it has never encountered.

These defenders employ sensors—known as recognition units—that are generated by chance in a vast number of combinations.

That provides the immune system the capacity to combat a broad range of threats, but the unpredictability of the mechanism inevitably creates white blood cells that may attack the body.

Protectors of the Body

Scientists earlier knew that a portion of these problematic white blood cells were eliminated in the immune organ—where immune cells mature.

The latest award recognizes the identification of regulatory T-cells—described as the body's "security guards"—which travel through the body to disarm other immune cells that attack the healthy cells.

It is known that this mechanism fails in autoimmune diseases such as type-1 diabetes, MS, and RA.

The Nobel panel stated, "These findings have established a novel area of investigation and accelerated the creation of new therapies, for instance for tumors and immune disorders."

Regarding cancer, T-regs block the system from fighting the tumor, so research are aimed at lowering their quantity.

In autoimmune diseases, experiments are exploring boosting regulatory T-cells so the organism is not under attack. A similar method could also be effective in reducing the risks of transplanted organ rejection.

Innovative Studies

Prof Sakaguchi, of Osaka University, conducted experiments on mice that had their thymus removed, causing autoimmune disease.

He showed that introducing defense cells from other animals could prevent the disease—suggesting there was a mechanism for blocking defenders from harming the host.

Mary Brunkow, from the Institute for Systems Biology in Seattle, and Dr. Ramsdell, now at Sonoma Biotherapeutics in a California city, were studying an inherited autoimmune disease in rodents and humans that led to the identification of a gene critical for how regulatory T-cells operate.

"Their groundbreaking research has uncovered how the body's defenses is controlled by T-reg cells, stopping it from mistakenly targeting the body's own tissues," said a prominent biological science expert.

"This research is a striking example of how fundamental physiological study can have far-reaching consequences for public health."